Drug
Lamotrigine
Lamotrigine: highest development phase Approved, developed by GlaxoSmithKline, Lupin, Zydus. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- GlaxoSmithKline, Lupin, Zydus
Trials
| Drug | Phase | Indication |
|---|---|---|
| LAMOTRIGINE | Approved | |
| lamotrigine, 300 mg/day NCT00355082 | Phase 3 | Epilepsy, Partial |
| Lamotrigine NCT00277641 | Phase 3 | Binge Eating Disorder |
| Lamotrigine NCT05639257 | Not Applicable | Non-Dystrophic Myotonia |
Latest
Follow Lamotrigine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.